Market Overview

Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership

Share:

Knight receives license to TX-004HR and TX-001HR and agrees to invest
$20 million in TherapeuticsMD

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a Canadian
specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that
they have entered into a licensing agreement that grants Knight the
rights to commercialize TX-004HR and TX-001HR in Canada and Israel.

TX-004HR is TherapeuticsMD's FDA-approved product, marketed as Imvexxy™
(estradiol vaginal inserts) in the U.S., for the treatment of
moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy (VVA), due to
menopause. TX-001HR is TherapeuticsMD's investigational bio-identical
hormone therapy combination of estradiol and progesterone in a single,
oral softgel for the treatment of moderate-to-severe vasomotor symptoms
due to menopause. According to the Society of Obstetricians and
Gynaecologists of Canada, vasomotor symptoms affect 60%-80% of women
entering menopause1 and it is estimated that 50% of
postmenopausal women suffer from VVA2.

Under the terms of the licensing agreement, Knight will pay
TherapeuticsMD a milestone fee upon first regulatory approval in Canada
of each of TX-004HR and TX-001HR, sales milestone fees based upon
certain aggregate annual sales in Canada and Israel of each of TX-004HR
and TX-001HR and royalties based on aggregate annual sales of each of
TX-004HR and TX-001HR in Canada and Israel. Knight will be responsible
for all regulatory and commercial activities in Canada and Israel
related to TX-004HR and TX-001HR.

In connection with the licensing agreement, Knight has agreed to invest
$20 million in TherapeuticsMD common stock concurrently with closing of
the first public offering of TherapeuticsMD common stock to occur within
sixty days following the date of the licensing agreement at a price per
share equal to the price to the public in such offering. If
TherapeuticsMD does not close such an offering then, instead of an
investment in TherapeuticsMD common stock, Knight will pay
TherapeuticsMD a previously negotiated upfront licensing fee.

About TX-004HR

TX-004HR was developed and approved in the U.S. as ImvexxyTM
(estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a symptom of
vulvar and vaginal atrophy (VVA), due to menopause. Imvexxy is the only
product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4
mcg represents the lowest approved dose of vaginal estradiol available.
Please visit www.imvexxy.com
for Full Prescribing Information, including boxed warning.

About TX-001HR

TX-001HR is TherapeuticsMD's investigational bio-identical hormone
therapy combination of estradiol and progesterone in a single, oral
softgel for the treatment of moderate-to-severe vasomotor symptoms due
to menopause.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company has recently received FDA approval for TX-004HR, marketed as
Imvexxy™ (estradiol vaginal inserts), for the treatment of moderate to
severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to
menopause. The company's late stage clinical pipeline includes TX-001HR
for treatment of moderate-to-severe vasomotor symptoms (VMS) due to
menopause. The company also manufactures and distributes branded and
generic prescription prenatal vitamins under the vitaMedMD® and
BocaGreenMD® brands.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a
specialty pharmaceutical company focused on acquiring or in-licensing
and commercializing innovative pharmaceutical products for the Canadian
and select international markets. Knight Therapeutics Inc.'s shares
trade on TSX under the symbol GUD. For more information about Knight
Therapeutics Inc., please visit the company's web site at www.gudknight.com
or www.sedar.com.

TherapeuticsMD Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking
statements. Forward-looking statements may include, but are not limited
to, statements relating to TherapeuticsMD's objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company intends,
expects, projects, believes or anticipates will or may occur in the
future. These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends," "plans,"
"will," "expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments made in
light of management's experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this press
release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a
result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties, many of which are outside of the company's
control. Important factors that could cause actual results, developments
and business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in the
company's filings with the Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: whether
the FDA will approve the NDA for the company's TX-001HR product
candidate and whether such approval will occur by the PDUFA target
action date; the company's ability to maintain or increase sales of its
products; the company's ability to develop and commercialize its hormone
therapy drug candidates and obtain additional financing necessary
therefor; whether the company will be able to comply with the covenants
and conditions under its term loan agreement; the length, cost and
uncertain results of the company's clinical trials; the potential of
adverse side effects or other safety risks that could preclude the
approval of the company's hormone therapy drug candidates; the company's
reliance on third parties to conduct its clinical trials, research and
development and manufacturing; the availability of reimbursement from
government authorities and health insurance companies for the company's
products; the impact of product liability lawsuits; the influence of
extensive and costly government regulation; the volatility of the
trading price of the company's common stock and the concentration of
power in its stock ownership. PDF copies of the company's historical
press releases and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.

Knight Forward-Looking Statement

This document contains forward-looking statements for Knight
Therapeutics Inc. and its subsidiaries. These forward-looking
statements, by their nature, necessarily involve risks and uncertainties
that could cause actual results to differ materially from those
contemplated by the forward-looking statements. Knight Therapeutics Inc.
considers the assumptions on which these forward-looking statements are
based to be reasonable at the time they were prepared, but cautions the
reader that these assumptions regarding future events, many of which are
beyond the control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could cause
actual results to differ materially from current expectations are
discussed in Knight Therapeutics Inc.'s Annual Report and in Knight
Therapeutics Inc.'s Annual Information Form for the year ended December
31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation
to update or revise any forward-looking statements whether as a result
of new information or future events, except as required by law.

1 Reid, Robert L., et al. "Menopause and Osteoporosis Update
2009.'' Journal of Obstetrics and Gynaecology Canada 2009, Volume 31,
11-12

2 Kingsberg, Sheryl A., et al. "Vulvar and Vaginal Atrophy in
Postmenopausal Women: Findings from the REVIVE (Real Women's Views of
Treatment Options for Menopausal Vaginal Changes) Survey." International
Society for Sexual Medicine 2013, no. 10, 1790-1799.

View Comments and Join the Discussion!